Lung Cancer

Clinical trials are cost-effective alternatives to current standard treatment

Published in Cancer Weekly, September 9th, 2003

Lung cancer patients who participate in clinical trials live longer than patients who receive standard therapy, with only a modest increase in cost.

The finding comes from a study published in the October 1, 2003, issue of Cancer, and provides the first evidence that clinical trials offer cost-effective treatments for non-small-cell lung cancer.

Lung cancer is the leading cause of cancer-related death in the United States, with 5-year survival rates of only 14%, a rate that has remained largely unchanged for decades, pointing to the limitations of current treatment modalities. Non-small-cell lung cancer is the most common type, accounting for...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-09-09)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry